Class Action Lawsuit Against Altimmune, Inc. Overview
Levi & Korsinsky, LLP has recently informed shareholders of Altimmune, Inc. ('Altimmune') about a class action lawsuit pertaining to alleged securities fraud. Investors are taking action to address their losses stemming from actions that occurred between August 10, 2023, and June 25, 2025.
Understanding the Class Definition
The lawsuit represents a collective effort from Altimmune investors adversely affected by the alleged deceptive practices. During this period, the company’s stock price was influenced by misleading statements, leading to significant financial impact on shareholders.
Key Details of the Case
On June 26, 2025, a critical press release revealed disappointing results from the company’s Phase 2b trial of Pemvidutide aimed at treating a specific type of liver disease. The released data did not meet the expectations set by the company leading up to the announcement. Although there were positive trends noted, the trial failed to achieve the necessary statistical significance. The higher-than-expected placebo response contributed to this disappointing outcome.
Market Response to the Trial Results
Following this news, the stock of Altimmune experienced a dramatic drop from $7.71 per share to $3.61 per share in a single day, marking a staggering decline of 53.2%. This significant loss prompted shareholders to seek legal recourse, initiating the class action lawsuit.
Next Steps for Affected Investors
Investors who experienced financial losses during the relevant period have until October 6, 2025, to request their appointment as lead plaintiff in this case. It’s important to note that participating in the recovery does not require one to serve as a lead plaintiff, allowing more investors to benefit from the lawsuit’s outcome.
Compensation Without Cost
For class members, participation in the lawsuit comes at no cost. Investors may recover compensation for their losses without any upfront fees or obligations, highlighting that there are no hidden costs associated with participating in this class action.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has garnered experience over the past two decades, specializing in securing substantial settlements for investors wronged in securities litigation. With a dedicated team and a proven track record, the firm ranks among the top firms in the United States according to several legal service reports.
Contact Information
For more information or to discuss potential participation in the class action, investors can reach out to:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: jlevi@levikorsinsky.com
Tel: (212) 363-7500
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit is aimed at recovering losses sustained by Altimmune investors due to alleged securities fraud.
What happened during the trial?
The trial results released did not meet investors' expectations, causing a significant drop in stock price, and prompting legal action.
Who can participate in the lawsuit?
Any investor who suffered losses during the specified period is eligible to participate without needing to become a lead plaintiff.
What are the deadlines to act on this lawsuit?
Investors must act before October 6, 2025, to request their roles in this lawsuit.
Is there any cost associated with participating in the lawsuit?
No, investors can pursue compensation without any upfront costs or fees.
